Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$69.06−5.12 (-6.90%)
Close on Nov 18, 2026Market cap $1.02BP/E –Yield –
Inhibrx Biosciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Inhibrx Biosciences's profit margin for the twelve months ending Dec 31, 2025 was -10773.5%. For fiscal 2025 it was -10773.5%, against 843786.0% the year before. The highest annual figure on record is 843786.0% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -10773.5% | −854559.5 |
| FY2024 | Dec 31, 2024 | 843786.0% | +857194.9 |
| FY2023 | Dec 31, 2023 | -13408.9% | −6783.7 |
| FY2022 | Dec 31, 2022 | -6625.3% | −5494.5 |
| FY2021 | Dec 31, 2021 | -1130.8% | −540.1 |
| FY2020 | Dec 31, 2020 | -590.7% | −201.6 |
| FY2019 | Dec 31, 2019 | -389.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -1936.6% | +3791.9 |
| Q2 FY2025 | Jun 30, 2025 | -2204.2% | +41316.0 |
| Q4 FY2024 | Dec 31, 2024 | -47865.0% | +108975.0 |
| Q2 FY2024 | Jun 30, 2024 | 1858011.0% | +2145752.2 |
| Q4 FY2023 | Dec 31, 2023 | -5728.5% | +9204.0 |
| Q3 FY2023 | Sep 30, 2023 | -43520.2% | −30813.3 |
| Q2 FY2023 | Jun 30, 2023 | -156840.0% | −151533.1 |
| Q1 FY2023 | Mar 31, 2023 | -287741.2% | −284376.9 |
| Q4 FY2022 | Dec 31, 2022 | -14932.5% | −14190.6 |
| Q3 FY2022 | Sep 30, 2022 | -12706.8% | −11894.0 |
| Q2 FY2022 | Jun 30, 2022 | -5306.9% | −3136.0 |
| Q1 FY2022 | Mar 31, 2022 | -3364.3% | −1194.5 |
| Q4 FY2021 | Dec 31, 2021 | -741.9% | −106.1 |
| Q3 FY2021 | Sep 30, 2021 | -812.8% | −465.4 |
| Q2 FY2021 | Jun 30, 2021 | -2170.9% | −1635.2 |
| Q1 FY2021 | Mar 31, 2021 | -2169.7% | +134.5 |
| Q4 FY2020 | Dec 31, 2020 | -635.8% | +5563.8 |
| Q3 FY2020 | Sep 30, 2020 | -347.3% | +1306.7 |
| Q2 FY2020 | Jun 30, 2020 | -535.6% | – |
| Q1 FY2020 | Mar 31, 2020 | -2304.2% | – |
| Q4 FY2019 | Dec 31, 2019 | -6199.6% | – |
| Q3 FY2019 | Sep 30, 2019 | -1654.1% | – |
See a number that looks wrong?